Enabling RNA therapeutics: innovative cationic lipids to improve LNP formulation

DNA and RNA therapeutics are drug products composed of an active genetic component linked to an efficient delivery system, generally lipid nanoparticles (LNPs). Those treatments include both prophylactic vaccines that prevent infection by triggering the patient’s immune system and therapeutic vaccines that will be used to treat and cure patients.

Each therapy will require its own LNP formulation depending on the genetic material and targeted tissue. To ensure therapeutic success, exploring a variety of lipids is key to modulating encapsulation efficiency and LNP properties.

Join this webinar to learn about new formulations to overcome current limitations of ionizable lipids by enabling a wider in vivo biodistribution and decreasing accumulation in the liver.

Attend this webinar to discover:

• How LNP delivery systems can be adapted to meet the unique needs of each therapy
• Why adding positive charges to an LNP can improve potency and targeting
• How LipidBrick® IM21.7c aims to improve LNP formulation to meet the growing demands of the mRNA therapeutic market

Claire Gueguen

R&D Life Science Manager, Polyplus

Claire is the Head of R&D Life Science at Polyplus. Before joining Polyplus-transfection, she held a position as Senior Scientist in the Cell Research team and then in the Allogeneic team at Adaptimmune where she worked on TCR T-cell therapy. She received her Ph.D. in Immunology from the University of Paris-Saclay in collaboration with Stallergenes Greer.

Malik Hellal

Director of Chemistry R&D, Polyplus

Malik Hellal is a Senior Scientist in Chemistry at Polyplus-transfection®. With a PhD in Organic and Medicinal chemistry from the University of Strasbourg, a post-doctoral experience at Harvard NeuroDiscovery Center, and a Marie Curie fellow position at the Institut de Science et d’ingénierie Supramoléculaire, Malik is an expert in the conception and synthesis of biopolymers for the development of innovative targeted delivery solutions.

Julien Depollier

Director of Strategic Partnerships, Polyplus

Julien has a Ph.D. in Biochemistry and Cellular Biology from University of Montpellier II (France, 2004). With 15+ year experience in Life Science industry and 10+ years with Polyplus transfection^®, mainly as Business Director Americas from 2013 to 2020. Since 2021, Julien has evolved to a more Strategic role in the company to develop alternative sales strategy and Business Partners across key Life Science market segments (Cell & Gene Therapy and others).

Watch now

SPEAKERS

Claire Gueguen

R&D Life Science Manager, Polyplus

Malik Hellal

Director of Chemistry R&D, Polyplus

Julien Depollier

Director of Strategic Partnerships, Polyplus

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 63

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 42

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 41

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 34

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 28

Days

Register